CN104684889A - 二甲双胍的三盐形式 - Google Patents

二甲双胍的三盐形式 Download PDF

Info

Publication number
CN104684889A
CN104684889A CN201380046842.4A CN201380046842A CN104684889A CN 104684889 A CN104684889 A CN 104684889A CN 201380046842 A CN201380046842 A CN 201380046842A CN 104684889 A CN104684889 A CN 104684889A
Authority
CN
China
Prior art keywords
compound
metformin
subject
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380046842.4A
Other languages
English (en)
Chinese (zh)
Inventor
B.L.米拉里
F.C.夏沃利诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xi Disi Pharmaceutical Co
Original Assignee
Xi Disi Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,970 external-priority patent/US8765811B2/en
Application filed by Xi Disi Pharmaceutical Co filed Critical Xi Disi Pharmaceutical Co
Publication of CN104684889A publication Critical patent/CN104684889A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380046842.4A 2012-07-10 2013-07-10 二甲双胍的三盐形式 Pending CN104684889A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261669763P 2012-07-10 2012-07-10
US61/669763 2012-07-10
US201261670368P 2012-07-11 2012-07-11
US201261670376P 2012-07-11 2012-07-11
US61/670368 2012-07-11
US61/670376 2012-07-11
US13/841,970 US8765811B2 (en) 2012-07-10 2013-03-15 Tri-salt form of metformin
US13/841970 2013-03-15
PCT/US2013/049984 WO2014011814A1 (en) 2012-07-10 2013-07-10 Tri-salt form of metformin

Publications (1)

Publication Number Publication Date
CN104684889A true CN104684889A (zh) 2015-06-03

Family

ID=49916541

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380046842.4A Pending CN104684889A (zh) 2012-07-10 2013-07-10 二甲双胍的三盐形式

Country Status (12)

Country Link
EP (1) EP2872483A4 (enExample)
JP (1) JP2015523382A (enExample)
KR (1) KR20150036235A (enExample)
CN (1) CN104684889A (enExample)
AU (1) AU2013290168A1 (enExample)
BR (1) BR112015000368A2 (enExample)
CA (1) CA2878819A1 (enExample)
IL (1) IL236613A0 (enExample)
IN (1) IN2015KN00076A (enExample)
MX (1) MX2015000408A (enExample)
WO (1) WO2014011814A1 (enExample)
ZA (1) ZA201500274B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114349665A (zh) * 2021-11-30 2022-04-15 青岛博创生物科学研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用
CN115192625A (zh) * 2022-06-30 2022-10-18 山东海赜生物科技有限公司 一种口服组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124141A1 (en) * 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
EA201692548A1 (ru) * 2014-06-18 2017-10-31 ТЕТИС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Минеральные аминокислотные комплексы активных веществ
US20170119841A1 (en) * 2015-11-04 2017-05-04 Thetis Pharmaceuticals Llc Amino acid salts of unsaturated fatty acids
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
US10471963B2 (en) 2017-04-07 2019-11-12 TuSimple System and method for transitioning between an autonomous and manual driving mode based on detection of a drivers capacity to control a vehicle
US10737695B2 (en) 2017-07-01 2020-08-11 Tusimple, Inc. System and method for adaptive cruise control for low speed following
CN113105367B (zh) 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012177A1 (en) * 2000-08-03 2002-02-14 Igor Anatolievich Pomytkin Composition of metformin with succinic acid or salts thereof and method for treating diabetes
US6372790B1 (en) * 1998-02-12 2002-04-16 Merck Patent Gesellschaft Mit Beschrankter Haftung Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
US20060159746A1 (en) * 2003-03-18 2006-07-20 Troup John P Compositions comprising fatty acids and amino acids
CN101855204A (zh) * 2007-09-21 2010-10-06 韩兀生物制药株式会社 N,n-二甲基亚氨二羰酸二酰胺二羧酸盐、其制备方法及其药物组合物
WO2010127099A2 (en) * 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
EP2229158B1 (en) * 2007-12-20 2016-08-10 Fertin Pharma A/S Compressed chewing gum tablet
US20110082119A1 (en) * 2008-06-13 2011-04-07 Takashi Yano Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
WO2012054523A2 (en) * 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2014124141A1 (en) * 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372790B1 (en) * 1998-02-12 2002-04-16 Merck Patent Gesellschaft Mit Beschrankter Haftung Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
WO2002012177A1 (en) * 2000-08-03 2002-02-14 Igor Anatolievich Pomytkin Composition of metformin with succinic acid or salts thereof and method for treating diabetes
US20060159746A1 (en) * 2003-03-18 2006-07-20 Troup John P Compositions comprising fatty acids and amino acids
CN101855204A (zh) * 2007-09-21 2010-10-06 韩兀生物制药株式会社 N,n-二甲基亚氨二羰酸二酰胺二羧酸盐、其制备方法及其药物组合物
WO2010127099A2 (en) * 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114349665A (zh) * 2021-11-30 2022-04-15 青岛博创生物科学研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用
CN115192625A (zh) * 2022-06-30 2022-10-18 山东海赜生物科技有限公司 一种口服组合物

Also Published As

Publication number Publication date
WO2014011814A1 (en) 2014-01-16
EP2872483A4 (en) 2016-03-16
IL236613A0 (en) 2015-02-26
ZA201500274B (en) 2017-10-25
BR112015000368A2 (pt) 2017-06-27
EP2872483A1 (en) 2015-05-20
IN2015KN00076A (enExample) 2015-07-31
AU2013290168A1 (en) 2015-02-05
KR20150036235A (ko) 2015-04-07
JP2015523382A (ja) 2015-08-13
CA2878819A1 (en) 2014-01-16
MX2015000408A (es) 2015-07-14

Similar Documents

Publication Publication Date Title
CN104684889A (zh) 二甲双胍的三盐形式
TWI621624B (zh) 合成的三萜系化合物及其使用於治療疾病之方法
AU2012205547B2 (en) Lipid-lowering antidiabetic agent
US8933124B2 (en) Tri-salt form of metformin
SK14922002A3 (sk) Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru
JP2006512334A (ja) Ｄｐｐ−ｉｖ阻害剤とｐｐａｒ−アルファ化合物の組み合わせ
JP2010535158A (ja) Ｓ−アリルシステインまたはそのアナローグの使用およびそれらの医薬組成物
WO2014008374A2 (en) Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents
KR101567660B1 (ko) 진성 당뇨병을 치료하기 위한 병용제
US20120295973A1 (en) Methods and compositions of derivatives of probucol for the treatment of diabetes
US9382187B2 (en) Tri-salt form of metformin
KR20230136627A (ko) 포유 동물에서 체중 감소를 유도하기 위한 외인성 케톤 에스테르의 용도
CN104557944B (zh) 一种降糖药物及其制备方法
WO2014008379A2 (en) Diamine and meglumine salt forms of fatty acids
US8440723B2 (en) Metformin salts of salicylic acid and its congeners
US20060004096A1 (en) Method of Treating Endothelial Dysfunction, Oxidative Stress and Related Diseases
US20080280985A1 (en) Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
MX2014014317A (es) Un metodo para mejorar la funcion hepatica.
US20130317034A1 (en) Combination therapy for treating diabetes
RU2537227C1 (ru) Гепатопротектор для лечения неалкогольного жирового гепатоза при сахарном диабете 2 типа
EP1757287A1 (en) Pharmaceutical composition for prevention or treatment of lipid metabolism disorder
JP2021024826A (ja) 糖化産物生成抑制剤及び医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20171117